The Molecular Basis of Hemophilia A: Genotype-Phenotype Relationships and Inhibitor Development

ABSTRACT

The molecular basis of hemophilia A has been extensively studied over the last two decades, and this analysis of the factor VIII (FVIII) gene has rendered it one of the most studied of all human genes. A wide range of different mutation types has been identified that includes the novel intrachromosomal inversions involving regions in introns 1 and 22 of the FVIII gene as well as many mutation types found in other genetic diseases, including large and small deletions and insertions, and point mutations resulting in nonsense, missense, and splice site mutations. Inhibitory antibodies that develop in a proportion of patients with hemophilia A following replacement therapy are now known to correlate with FVIII mutation type and location. This correlation is demonstrated, and a potential algorithm for predicting inhibitor development in newly diagnosed patients is presented. Many patients with mild hemophilia A have a discrepancy between the levels of FVIII:C determined by the one-stage and two-stage assays. The molecular basis of the discrepancy is explored. This article thus highlights both the molecular basis of hemophilia and some of the additional information that can be gained from determination of the mutation responsible for hemophilia in affected patients.

KEYWORD

Mutation - inhibitors - factor VIII gene - inversion

REFERENCES

• 1 Gitschier J, Wood W I, Goralka T M. et al . Characterization of the human factor VIII gene Nature.  1984;  312 326-330
• 2 Wood W I, Capon D J, Simonsen C C. et al . Expression of active human factor VIII from recombinant DNA clones.  Nature . 1984;  312 330-337
• 3 Toole J J, Knopf J L, Wozney J M. et al . Molecular cloning of a cDNA encoding human antihaemophilic factor.  Nature . 1984;  312 342-347
• 4 Gitschier J, Wood W I, Tuddenham E G. et al . Detection and sequence of mutations in the factor VIII gene of haemophiliacs.  Nature . 1985;  315 427-430
• 5 Lewin B. Genes V.  Oxford: Oxford University Press 1994
• 6 Shima M, Ware J, Yoshioka A, Fukui H, Fulcher C A. An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule.  Blood . 1989;  74 1612-1617
• 7 Jaquemin M, Lavend'homme R, Benhida A. et al . A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor Blood .  2000;  96 958-965
• 8 Frischmeyer P A, Dietz H C. Nonsense-mediated mRNA decay in health and disease.  Hum Mol Genet . 1999;  8 1893-1900
• 9 van de Water N, Williams R, Ockelford P, Browett P. A 20.7 kb deletion within the factor VIII gene associated with LINE-1 element insertion.  Thromb Haemost . 1998;  79 938-942
• 10 Vidal F, Farssac E, Tusell J, Puig L, Gallardo D. First molecular characterization of an unequal homologous Alu-mediated recombination event responsible for hemophilia.  Thromb Haemost . 2002;  88 12-16
• 11 Sommer S S, Scaringe W A, Hill K A. Is Alu-mediated recombination an important cause of hemophilia?.  Thromb Haemost . 2002;  88 3-4
• 12 Kazazian H H, Wong C, Youssoufian H. et al . Haemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man.  Nature . 1998;  332 164-166
• 13 Sukarova E, Dimovski A J, Tchacarova P, Petkov G H, Efremov G D. An Alu insert as the cause of a severe form of hemophilia A.  Acta Haematol . 2001;  106 126-129
• 14 Cooper D N, Krawczak M, Antonarakis S E. The nature and mechanisms of human gene mutation. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer New York: McGraw Hill 1998
• 15 Tavassoli K, Eigel A, Wilke K, Pollmann H, Horst J. Molecular diagnostics of 15 hemophilia A patients: characterization of eight novel mutations in the factor VIII gene, two of which result in exon skipping.  Hum Mutat . 1998;  12 301-303
• 16 Bagnall R D, Waseem N H, Green P M. et al . Creation of a novel donor splice site in intron 1 of the factor VIII gene leads to activation of a 191 bp cryptic exon in two haemophilia A patients.  Br J Haematol . 1999;  107 766-771
• 17 Lakich D, Kazazian Jr H H, Antonarakis S E, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A.  Nat Genet . 1993;  5 236-241
• 18 Naylor J, Brinke A, Hassock S, Green P M, Giannelli F. Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions.  Hum Mol Genet . 1993;  2 1773-1778
• 19 Bagnall R D, Waseem N, Green P M, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A.  Blood . 2002;  99 168-174
• 20 Rossiter J P, Young M, Kimberland M L. et al . Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells.  Hum Mol Genet . 1994;  3 1035-1039
• 21 Antonarakis S E, Rossiter J P, Young M. et al . Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.  Blood . 1995;  86 2206-2212
• 22 Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations.  Thromb Haemost . 2001;  85 580-583
• 23 Williams I J, Abuzenadah A, Winship P R. et al . Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis.  Thromb Haemost . 1998;  79 723-726
• 24 Oldenburg J, Ivaskevicius V, Rost S. et al . Evaluation of DHPLC in the analysis of hemophilia A.  J Biochem Biophys Methods . 2001;  47 39-51
• 25 Schwaab R, Brackmann H H, Meyer C. et al . Haemophilia A: mutation type determines risk of inhibitor formation.  Thromb Haemost . 1995;  74 1402-1406
• 26 Goodeve A C, Williams I, Bray G L, Peake I R, for the Recombinate PUP Study Group. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate).  Thromb Haemost . 2000;  83 844-888
• 27 Young M, Inaba H, Hoyer L W. et al . Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene.  Am J Hum Genet . 1997;  60 565-573
• 28 Denson K WE, Biggs R. Laboratory diagnosis, tests of clotting function and their standardisation. In: Biggs R, ed. Human Blood Coagulation, Haemostasis and Thrombosis Oxford: Blackwell Scientific Publications 1976: 310-364
• 29 Hathaway W E, Christian M J, Jacobson L J. Variant mild haemophilia. Discrepancy in one stage and two stage factor VIII assays (Abst).  Thromb Haemost . 1983;  50 357
• 30 Duncan E M, Duncan B M, Tunbridge L J, Lloyd J V. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A.  Br J Haematol . 1994;  87 846-848
• 31 Rudski Z, Duncan E M, Casey G J. et al . Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods.  Br J Haematol . 1996;  94 400-406
• 32 Pipe S P, Saenko E L, Eickhorst A N, Kemball-Cook G, Kaufman R J. Hemophilia A mutations associated with 1-/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.  Blood . 2001;  97 685-691
• 33 Nesbitt I M, Hinks J L, Sampson B. et al . Discrepant one and two stage FVIII assays are very common in mild haemophilia A: correlation with FVIII gene mutations (Abst).  Thromb Haemost . 2001;  (Suppl) A5674
• 34 Pemberton S, Lindley P, Zaitsev V. et al . A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin.  Blood . 1997;  89 2413-2421